Could one engineered protein format address tumor-cell death and inhibitory checkpoint signaling?
UC Davis describes engineered human cytomegalovirus protein-derived variants that engage DR5 and sequester CD155. The design aims to couple a tumor-cell death signal with reduced TIGIT inhibitory engagement. It is a published technology disclosure, not a peer-reviewed clinical result.
DR5 is a death receptor; CD155 can bind TIGIT on immune cells. The disclosure proposes addressing both axes in one biologic format.
Evidence and methods
The public disclosure describes engineered variants and mechanistic intent. It does not provide a complete peer-reviewed methods and efficacy record suitable for independent quantitative comparison.
Dual-action design is disclosed
UC Davis states that the variants activate DR5 signaling and sequester CD155 in described experiments.
An international application is published
The disclosure lists PCT publication WO2024/050058, published March 7, 2024.
Inside the study
Two-axis proposal
The published UC disclosure proposes an engineered viral-protein-derived format that engages DR5 and sequesters CD155. The latter is intended to reduce access to inhibitory TIGIT signaling.
Interpretation
The proposed design links receptor clustering to CD155 sequestration. Claims of clinical superiority in the marketing disclosure should be treated as a proposed benefit, not demonstrated patient benefit.
Evidence stage
Invention disclosure and published application. Clinical safety, efficacy and licensing status are not established by the public listing.
Paper and research team
Contributors
Inventors are listed in the linked technology record.